Please assess the completion status of the following clinical trial:

Trial Title: Phase 3 Pivotal Trial of NanoFlu™ in Older Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Clinically-stable adult male or female, ≥ 65 years of age. Subjects may have 1 or more chronic medical diagnoses, but should be clinically stable as assessed by:~   * Ambulatory status, living independently in the community or in a residential facility providing minimal assistance (eg, meal preparation and transport),~  * Absence of changes in medical therapy within 1 month due to treatment failure or toxicity,~  * Absence of medical events qualifying as serious adverse events within the prior 2 months, and~  * Absence of known, current, and life-limiting diagnoses which render survival to completion of the protocol unlikely in the opinion of the investigator.~2. Willing and able to give informed consent prior to trial enrollment, and~3. Living in the community and able to attend trial visits, comply with trial requirements, and provide timely, reliable, and complete reports of adverse events.~Exclusion Criteria:~1. Participation in research involving investigational product (drug / biologic / device) within 45 days before planned date of study vaccination.~2. Participation in any previous Novavax influenza vaccine clinical trial(s).~3. History of a serious reaction to prior influenza vaccination, known allergy to constituents of Fluzone Quadrivalent or polysorbate 80.~4. History of Guillain-Barré Syndrome (GBS) within 6 weeks following a previous influenza vaccine.~5. Received any vaccine in the 4 weeks preceding the trial vaccination and any influenza vaccine within 6 months preceding the trial vaccination.~6. Any known or suspected immunosuppressive illness, congenital or acquired, based on medical history and/or physical examination.~7. Chronic administration (defined as more than 14 continuous days) of immunosuppressants or other immune-modifying drugs within 6 months prior to the administration of the trial vaccine. An immunosuppressant dose of glucocorticoid will be defined as a systemic dose ≥ 10 mg of prednisone per day or equivalent. The use of topical, inhaled, and nasal glucocorticoids will be permitted.~8. Administration of immunoglobulins and/or any blood products within the 3 months preceding the administration of the trial vaccine.~9. Acute disease at the time of enrollment (defined as the presence of a moderate or severe illness with or without fever, or an oral temperature ≥ 38.0°C, on the planned day of vaccine administration).~10. Any condition that in the opinion of the investigator would pose a health risk to the subject if enrolled or could interfere with evaluation of the vaccine or interpretation of trial results (including neurologic or psychiatric conditions deemed likely to impair the quality of safety reporting).~11. Known disturbance of coagulation.~12. Suspicion or recent history (within 1 year of planned vaccination) of alcohol or other substance abuse.

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- NanoFlu (Type: EXPERIMENTAL): NanoFlu will be administered as a single dose (0.5 mL) in the arm muscle on Day 0.
- Fluzone Quadrivalent (Type: ACTIVE_COMPARATOR): Fluzone Quadrivalent will be administered as a single dose (0.5 mL) in the arm muscle on Day 0.

Based on this trial design, predict the completion outcome and termination type (if applicable).